Capricor Therapeutics Inc (OTCMKTS:CAPR) is scheduled to be posting its quarterly earnings results on Monday, August 14th. Analysts expect Capricor Therapeutics to post earnings of ($0.18) per share for the quarter.

Capricor Therapeutics (OTCMKTS:CAPR) last issued its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.02. The firm had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $0.87 million. On average, analysts expect Capricor Therapeutics to post $-0.74 EPS for the current fiscal year and $-0.83 EPS for the next fiscal year.

Capricor Therapeutics Inc (CAPR) opened at 1.14 on Monday. Capricor Therapeutics Inc has a 1-year low of $0.63 and a 1-year high of $4.09. The company has a 50-day moving average of $0.86 and a 200-day moving average of $2.07. The company’s market capitalization is $25.76 million.

A number of equities research analysts recently weighed in on the stock. HC Wainwright set a $2.00 price objective on shares of Capricor Therapeutics and gave the company a “buy” rating in a report on Tuesday, July 18th. Zacks Investment Research upgraded shares of Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a report on Monday, April 17th. Rodman & Renshaw reiterated a “buy” rating and set a $2.15 price objective on shares of Capricor Therapeutics in a report on Saturday, July 22nd. Finally, ValuEngine lowered shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $4.91.

In other Capricor Therapeutics news, major shareholder Sinai Medical Center Cedars purchased 1,145,161 shares of Capricor Therapeutics stock in a transaction dated Tuesday, May 9th. The stock was acquired at an average price of $3.10 per share, for a total transaction of $3,549,999.10. Following the acquisition, the insider now owns 4,049,959 shares in the company, valued at approximately $12,554,872.90. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Louis Manzo purchased 10,000 shares of Capricor Therapeutics stock in a transaction dated Tuesday, May 9th. The stock was acquired at an average price of $3.10 per share, with a total value of $31,000.00. Following the acquisition, the director now owns 138,384 shares in the company, valued at approximately $428,990.40. The disclosure for this purchase can be found here.

COPYRIGHT VIOLATION WARNING: “Capricor Therapeutics Inc (OTCMKTS:CAPR) to Release Earnings on Monday” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/07/capricor-therapeutics-inc-otcmktscapr-to-release-earnings-on-monday.html.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Earnings History for Capricor Therapeutics (OTCMKTS:CAPR)

Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.